Stelara dose escalation effective, safe in luminal, perianal Crohn’s disease

AUSTIN, Texas — Real-world dose escalation of Stelara was safe and effective in patients with perianal Crohn’s disease, according to data presented at Crohn’s and Colitis Congress.“Standard ustekinumab dosing is every 8 weeks for moderate to severe Crohn’s disease, but in real-world practice a lot of physicians will dose escalate to every 4 or every 6 weeks in patients who aren’t meeting a clinical response,” Jason Glass, MD, a fellow at University of Texas Southwestern Medical Center, told Healio Gastroenterology and Liver Disease. “But there’sRead More

Share on facebook
Share on twitter
Share on linkedin